PlumX Metrics
Embed PlumX Metrics

Lifespan effects in male UM-HET3 mice treated with sodium thiosulfate, 16-hydroxyestriol, and late-start canagliflozin

GeroScience, ISSN: 2509-2723, Vol: 46, Issue: 5, Page: 4657-4670
2024
  • 3
    Citations
  • 2
    Usage
  • 3
    Captures
  • 1
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Most Recent News

Findings in Sodium-Glucose Transporter 2 Inhibitors Reported from University of Michigan (Lifespan Effects In Male Um-het3 Mice Treated With Sodium Thiosulfate, 16-hydroxyestriol, and Late-start Canagliflozin)

2024 JUN 17 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Drug Daily -- Current study results on Drugs and Therapies - Sodium-Glucose

Article Description

Genetically heterogeneous UM-HET3 mice born in 2020 were used to test possible lifespan effects of alpha-ketoglutarate (AKG), 2,4-dinitrophenol (DNP), hydralazine (HYD), nebivolol (NEBI), 16α-hydroxyestriol (OH_Est), and sodium thiosulfate (THIO), and to evaluate the effects of canagliflozin (Cana) when started at 16 months of age. OH_Est produced a 15% increase (p = 0.0001) in median lifespan in males but led to a significant (7%) decline in female lifespan. Cana, started at 16 months, also led to a significant increase (14%, p = 0.004) in males and a significant decline (6%, p = 0.03) in females. Cana given to mice at 6 months led, as in our previous study, to an increase in male lifespan without any change in female lifespan, suggesting that this agent may lead to female-specific late-life harm. We found that blood levels of Cana were approximately 20-fold higher in aged females than in young males, suggesting a possible mechanism for the sex-specific disparities in its effects. NEBI was also found to produce a female-specific decline (4%, p = 0.03) in lifespan. None of the other tested drugs provided a lifespan benefit in either sex. These data bring to 7 the list of ITP-tested drugs that induce at least a 10% lifespan increase in one or both sexes, add a fourth drug with demonstrated mid-life benefits on lifespan, and provide a testable hypothesis that might explain the sexual dimorphism in lifespan effects of the SGLT2 inhibitor Cana.

Bibliographic Details

Miller, Richard A; Harrison, David E; Cortopassi, Gino A; Dehghan, Ishmael; Fernandez, Elizabeth; Garratt, Michael; Geisler, John G; Ginsburg, Brett C; Han, Melissa L; Kaczorowski, Catherine C; Kumar, Navasuja; Leiser, Scott F; Lopez-Cruzan, Marisa; Milne, Ginger; Mitchell, James R; Nelson, James F; Reifsnyder, Peter C; Salmon, Adam B; Korstanje, Ron; Rosenthal, Nadia; Strong, Randy

Springer Science and Business Media LLC

Biochemistry, Genetics and Molecular Biology; Veterinary; Medicine

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know